L. Cao

CMAR_A_207167 6855..6869

Wansong Lin, Mingang Ying, Y. Ye, 2019 .

Arsenic Trioxide Nanoparticles Loaded with miR-423-5p Mediate Macrophage Autophagy and Anti-MTB Inflammatory Response

Xiang Yu, Lu Gu, Lizhou Wang, 2022, Journal of Biomedical Nanotechnology.

LBA4 GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

H. Shen, Yan Yu, Yan Sun, 2020, Annals of Oncology.

Comparing Nanoparticle Polymeric Micellar Paclitaxel and Solvent-based Paclitaxel as First-line Treatment of Advanced Non-Small Cell Lung Cancer: An Open-label, Randomized, Multicenter, Phase III Trial.

Y. Wu, X. Wang, Z. Guo, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

2MO Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC

H. Zhang, N. Yang, Yuxiang Chen, 2022, Annals of Oncology.

MA14.05 A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)

Ying Cheng, C. Bai, Jin-Ji Yang, 2019, Journal of Thoracic Oncology.

P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC

X. Jiang, J. Fang, F. Wu, 2021 .

OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

X. Jiang, J. Fang, C. Zhu, 2019, Journal of Thoracic Oncology.